Evolent Health (NYSE:EVH) received mixed analyst ratings, with 4 analysts offering views ranging from bullish to somewhat bullish over the last three months. The average 12-month price target is $40.5, a decrease from the previous target, reflecting a 5.09% decline. Analyst actions include both upgrades and downgrades, with price targets ranging from $37.00 to $45.00. Evolent Health, engaged in healthcare delivery and payment, has shown strong financial performance with a revenue growth rate of 44.93% and above-average market capitalization, despite a net margin of -6.5% and an ROE of -3.03%.